# Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

> **NCT02412098** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 49 (actual)

## Conditions studied

- Long QT Syndrome

## Interventions

- **DRUG:** Eleclazine

## Key facts

- **NCT ID:** NCT02412098
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-19
- **Primary completion:** 2016-04-22
- **Final completion:** 2016-04-22
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412098, "Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02412098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*